ADRB2 and pulmonary fibrosis: Adrb2 inhibition with ICI-118,551 can be a therapy for pulmonary fibrosis, while the combination of NAC with ICI-118,551 increased the efficacy, which might be a potential therapy for pulmonary fibrosis.